NCT02020434View on ClinicalTrials.gov

The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
Subjects With Varying Degrees of Renal Insufficiency andSubjects With Normal Renal Function
Interventions
DRUG

RPX7009 and RPX2014

The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.

Trial Locations (2)

55404

DaVita Clinical Research, Minneapolis

80228

DaVita Clinical Research, Lakewood

All Listed Sponsors
lead

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

INDUSTRY

NCT02020434 - The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency | Biotech Hunter | Biotech Hunter